Drug Profile
Research programme: outer membrane protein targeting antibiotics - Basilea Pharmaceutica
Alternative Names: OMPTA - Spexis; OMPTA BamA program - Spexis; Outer membrane protein targeting antibiotics - Spexis; PEM - Spexis; POL 7001; POL-0067; POL-6137; Protein epitope mimetic molecules - SpexisLatest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Polyphor; University of Zurich
- Developer Basilea Pharmaceutica
- Class Antibacterials; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics
- Mechanism of Action Bacterial outer membrane protein modulators; Imp protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 15 Jan 2024 Basilea Pharmaceutica acquires antibacterials research programme from Spexis
- 07 Jun 2023 Antibacterial research programme is still in preclinical phase for Gram negative infections in Switzerlands
- 07 Jun 2023 Pharmacodynamics, adverse events and antimicrobial data from preclinical trial in Gram-negative infections released by Spexis